Get the Stockscreener App
2.95
1.34%
-0.04
After Hours:
2.94
-0.01
-0.34%
Akebia Therapeutics Inc stock is traded at $2.95, with a volume of 2.25M.
It is down -1.34% in the last 24 hours and down -11.14% over the past month.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
See More
Previous Close:
$2.99
Open:
$2.99
24h Volume:
2.25M
Relative Volume:
0.55
Market Cap:
$782.18M
Revenue:
$194.75M
Net Income/Loss:
$-51.26M
P/E Ratio:
-10.54
EPS:
-0.28
Net Cash Flow:
$-23.38M
1W Performance:
-0.34%
1M Performance:
-11.14%
6M Performance:
+52.85%
1Y Performance:
+104.86%
1-Day Range:
$2.91
$2.99
1-Week Range:
$2.91
$3.15
52-Week Range:
$1.24
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Name
Akebia Therapeutics Inc
Sector
Phone
617-871-2098
Address
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
2.95 | 776.87M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
148.20 | 66.22B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.93 | 22.45B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
405.02 | 17.93B | 2.99B | 1.21B | 1.13B | 25.06 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Resumed | H.C. Wainwright | Buy |
| Apr-28-25 | Initiated | Leerink Partners | Outperform |
| Apr-01-25 | Initiated | Jefferies | Buy |
| Nov-29-23 | Resumed | BTIG Research | Buy |
| Aug-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-31-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-31-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-22 | Downgrade | Needham | Buy → Hold |
| Mar-31-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-19 | Reiterated | Needham | Buy |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-11-19 | Reiterated | H.C. Wainwright | Buy |
| May-02-19 | Initiated | JP Morgan | Overweight |
| Mar-20-19 | Initiated | Citigroup | Neutral |
| Sep-07-18 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-18 | Reiterated | Needham | Buy |
| Jun-06-18 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-17 | Initiated | Piper Jaffray | Overweight |
| Dec-07-17 | Initiated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-10-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | Needham | Buy |
| Dec-27-16 | Reiterated | H.C. Wainwright | Buy |
| Dec-20-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-15-16 | Initiated | Aegis Capital | Buy |
| Sep-29-16 | Initiated | Brean Capital | Buy |
| Mar-16-16 | Reiterated | Needham | Buy |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
View All
Akebia Therapeutics Inc Stock (AKBA) Latest News
134,277 Shares in Akebia Therapeutics, Inc. $AKBA Purchased by Alyeska Investment Group L.P. - MarketBeat
Jacobs Levy Equity Management Inc. Boosts Stock Holdings in Akebia Therapeutics, Inc. $AKBA - MarketBeat
Invesco Ltd. Purchases 139,957 Shares of Akebia Therapeutics, Inc. $AKBA - MarketBeat
Individual Investors Who Have a Significant Stake Must Be Disappointed Along With Institutions After Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Market Cap Dropped by US$50m - 富途牛牛
Retail investors who have a significant stake must be disappointed along with institutions after Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) market cap dropped by US$50m - simplywall.st
MetLife Investment Management LLC Buys 14,134 Shares of Akebia Therapeutics, Inc. $AKBA - Defense World
Akebia at H.C. Wainwright: Strategic Growth in Anemia Treatment By Investing.com - Investing.com Canada
Akebia at H.C. Wainwright: Strategic Growth in Anemia Treatment - Investing.com
Akebia Therapeutics Inc. Stock Poised for Technical ComebackWeekly Investment Recap & Free Expert Approved Momentum Trade Ideas - beatles.ru
Akebia outlines access to over 275,000 dialysis patients for Vafseo in Q4 as DaVita pilot launches - MSN
Does Akebia Therapeutics Inc. have pricing powerJuly 2025 Movers & High Accuracy Investment Entry Signals - beatles.ru
What are Akebia Therapeutics Inc.’s earnings expectationsMarket Volume Report & Consistent Income Trade Ideas - 뉴스영
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees - MSN
Nantahala Capital Management LLC Invests $3.84 Million in Akebia Therapeutics, Inc. $AKBA - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) most popular amongst individual investors who own 55% of the shares, institutions hold 43% - Yahoo Finance
Invesco Ltd. Acquires 139,957 Shares of Akebia Therapeutics, Inc. $AKBA - Defense World
Analysts Set Akebia Therapeutics, Inc. (NASDAQ:AKBA) Price Target at $6.75 - MarketBeat
How to interpret RSI for Akebia Therapeutics Inc. stockPortfolio Return Report & AI Enhanced Execution Alerts - Newser
Panic Selling: Is Akebia Therapeutics Inc. forming a bullish divergencePortfolio Gains Summary & Daily Stock Trend Watchlist - خودرو بانک
Can Akebia Therapeutics Inc. keep up with sector leadersTrade Analysis Summary & Scalable Portfolio Growth Methods - خودرو بانک
Is Akebia Therapeutics Inc. a strong candidate for buy and holdJuly 2025 Setups & Growth Oriented Trade Recommendations - خودرو بانک
Biotech Movers: Akebia Soars on Expanded Partnership With Otsuka - TheStreet
Detecting support and resistance levels for Akebia Therapeutics Inc.July 2025 PostEarnings & Advanced Swing Trade Entry Plans - Newser
Measuring Akebia Therapeutics Inc.’s beta against major indicesPortfolio Performance Summary & High Accuracy Buy Signal Tips - Newser
Wellington Management Group LLP Acquires 164,440 Shares of Akebia Therapeutics, Inc. $AKBA - MarketBeat
Akebia Therapeutics' Strategic Position in the Renal Therapeutics Market - AInvest
Transcript : Akebia Therapeutics, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-04-2025 08 - MarketScreener
Strategies to average down on Akebia Therapeutics Inc.2025 Bull vs Bear & Comprehensive Market Scan Reports - Newser
Akebia at Wells Fargo Conference: Strategic Growth in Healthcare - Investing.com
What is Akebia Therapeutics Inc. s 5 year growth outlookJuly 2025 Institutional & Stepwise Trade Execution Plans - خودرو بانک
Is Akebia Therapeutics Inc. forming a bottoming basePortfolio Growth Summary & Long-Term Investment Growth Plans - Newser
Is Akebia Therapeutics Inc. stock heavily shortedJuly 2025 News Drivers & Technical Buy Zone Confirmation - خودرو بانک
News impact scoring models applied to Akebia Therapeutics Inc.July 2025 Action & Fast Exit and Entry Strategy Plans - Newser
What Fibonacci levels say about Akebia Therapeutics Inc. reboundPortfolio Growth Summary & Real-Time Chart Pattern Alerts - Newser
What’s the recovery path for long term holders of Akebia Therapeutics Inc.Chart Signals & High Win Rate Trade Tips - Newser
Akebia Therapeutics, Inc. $AKBA Shares Purchased by Vanguard Group Inc. - MarketBeat
Will Akebia Therapeutics Inc. outperform the marketJuly 2025 Setups & Step-by-Step Trade Execution Guides - Newser
Using Python tools to backtest Akebia Therapeutics Inc. strategiesBond Market & Real-Time Stock Entry Alerts - Newser
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Regression analysis insights on Akebia Therapeutics Inc. performanceTrade Analysis Report & Long-Term Safe Investment Plans - Newser
Understanding Akebia Therapeutics Inc.’s price movementRecession Risk & High Return Stock Watch Alerts - Newser
Akebia Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Akebia Therapeutics shares rise 1.93% after-hours following inducement grants to new employees. - AInvest
95,100 Shares at $3.14: Akebia Therapeutics Grants Inducement Stock Options to Key New Hires - Stock Titan
Stock Report: Can Akebia Therapeutics Inc. stock outperform in a bear market2025 Earnings Surprises & Accurate Buy Signal Notifications - خودرو بانک
Does Akebia Therapeutics Inc. have declining or rising EPSJuly 2025 Price Swings & Verified Momentum Stock Ideas - خودرو بانک
Analyzing drawdowns of Akebia Therapeutics Inc. with statistical toolsJuly 2025 Short Interest & Fast Entry and Exit Trade Plans - Newser
Can Akebia Therapeutics Inc. stock outperform in a bear marketMarket Growth Review & High Win Rate Trade Tips - خودرو بانک
Akebia Therapeutics Inc. Stock Recovery Path — Analyst Breakdown2025 Momentum Check & Stock Market Timing Techniques - beatles.ru
Is Akebia Therapeutics Inc. reversing from oversold territoryJuly 2025 Trade Ideas & Fast Exit and Entry Strategy Plans - Newser
Akebia Therapeutics Inc Stock (AKBA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):